Announcement, From Bench to Fireside 01.24.24 Share on Twitter Share on Facebook Share on LinkedIn From T-Cell Research to Clinical Impact with Christopher A. Klebanoff, MD In this episode, physician-scientist Christopher Klebanoff, MD, a PICI Network Investigator at Memorial Sloan Kettering Cancer Center, provides an inside look at his groundbreaking research on optimizing T-cell activation for cancer immunotherapy. Dr. Klebanoff discusses his work on targeting mutated driver oncogenes, expanding cell therapies beyond blood cancers, and using CD4+ T cells to improve cancer outcomes. Tracing the evolution of the field from pioneers like Dr. William Coley to current leaders such as Nobel laureate Jim Allison, PhD, Center Director for the PICI Center at MD Anderson, Dr. Klebanoff explains why multidisciplinary collaboration is essential to driving progress in cancer immunotherapy. Get ready to go from bench to fireside with Dr. Klebanoff. Listen on Spotify Related Announcement PICI 2024: Collaborative Breakthroughs in Cancer Immunotherapy Announcement, Press Release Parker Institute Awards $525,000 to Advance Diverse Talent in Cancer Research Announcement PICI Network Investigators Propel Immunotherapy Progress at SITC 2024
Announcement, Press Release Parker Institute Awards $525,000 to Advance Diverse Talent in Cancer Research